NCT04689737View on ClinicalTrials.gov

Removal of Doravirine by Hemodialysis in HIV-Infected Patients With End-stage Renal Disease (ESRD)

PHASE4CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

March 20, 2021

Primary Completion Date

June 14, 2021

Study Completion Date

June 14, 2021

Conditions
HIV-infected Participants With ESRD Undergoing Routine Hemodialysis
Interventions
DRUG

Doravirine

Participants will be told to take one tablet of doravirine (Pifeltro, MDS) once daily, with or without food, approximately at the day time that they usually finish the hemodialysis sessions. The rest of their antiretroviral regimen and concomitant medications will remain unchanged

Trial Locations (3)

08916

Germans Trias i Pujol Hospital, Badalona

08907

Universitario Bellvitge Hospital, L'Hospitalet de Llobregat

08035

Valle Hebron Hospital, Barcelona

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia

OTHER

NCT04689737 - Removal of Doravirine by Hemodialysis in HIV-Infected Patients With End-stage Renal Disease (ESRD) | Biotech Hunter | Biotech Hunter